SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus as massive trading volume coincides with speculative interest in its recent $6.9 million counter-drone contract and a potential squeeze setup. Community members are divided, with many debating the stock's long-term defense sector fundamentals against intense short-selling pressure and concerns over share dilution.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending as investors actively track its move above the 200-day moving average and speculate on a potential short squeeze amid rising volume and analyst price target upgrades. The community remains deeply divided, with bulls pointing to strong operational growth and potential buybacks while bears warn of technical resistance, recurring sell-offs, and historical volatility.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is rallying on a surge in Bitcoin and broader crypto market momentum, fueled by growing anticipation surrounding the CLARITY Act. Investors and community members are actively debating whether this breakout is the start of a sustained reversal or another bull trap, with many closely tracking regulatory updates and institutional inflows.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending due to heightened retail debate regarding its long-term growth potential and price volatility, with investors actively discussing a significant disconnect between strong product demand and recent stock price weakness. The community remains polarized, with bulls viewing the current dip as a prime accumulation opportunity driven by brand expansion, while bears cite competitive pressures and margin concerns as reasons for continued downward movement.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is at the center of heated community debate as traders monitor developments regarding the potential passage of the Clarity Act and its expected impact on institutional adoption. Investors are divided between optimism over regulatory progress and skepticism fueled by ongoing price stagnation, with many actively debating whether the current market environment signals a bottom or further downside.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as investors aggressively position ahead of upcoming quarterly earnings, fueled by optimism regarding Amtagvi commercial uptake and potential regulatory catalysts for its NSCLC program. The community is actively discussing a surge in institutional accumulation and heavy trading volume, with many bulls viewing current price levels as a significant value opportunity despite ongoing volatility from short interest.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor Corp. is experiencing intense volatility as the market digests its recent quarterly earnings, with the community actively debating whether the current price represents a bargain or a warning sign after a steep post-earnings decline. Investors are fixated on guidance for product revenue growth, the status of its high-performance power modules in AI data centers, and legal developments concerning patent litigation that could impact future licensing revenue.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is experiencing significant investor attention following a federal executive order aimed at accelerating psychedelic research, combined with strategic leadership updates including the appointment of a new SVP of Medical Affairs. The community is actively debating the company's long-term outlook, weighing its Breakthrough Therapy status against concerns over recent leadership turnover, cash burn, and the potential for equity dilution.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is currently trending as investors weigh the potential of the commercial rollout of ZEVASKYN against recent price volatility and concerns regarding the pace of patient treatment scaling. Community members are actively debating the company's long-term commercial execution and the impact of the Qualified Treatment Center network expansion, with many viewing current price levels as a favorable entry point for a long-term position.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is currently facing significant volatility driven by an active proxy battle initiated by co-founder Toby Neugebauer and investor anticipation regarding the potential signing of an anchor tenant for their large-scale AI power infrastructure. While community sentiment is deeply divided between those betting on the company's long-term utility value and those frustrated by governance drama and recent financing news, the stock remains a high-conviction play for investors tracking hyperscaler demand and data center capacity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. It engages in the discovery and development of therapies designed to extend and enhance the quality of human life. The firm offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Athersys Inc

Neutral Sentiment

Too early to tell

Semiconductor stocks have been under significant selling pressure in recent weeks, leaving retail investors debating whether the worst is over or if more downside lies ahead. Cast your vote and let us know your reasoning in the comments.

Is the pullback in semiconductor stocks over? 
 
Explain your reasoning in the comments.

Current Price	$0.00
Prev Close	N/A
Open	N/A
Dividend Yield	N/A
50-Day Moving Average	$0.00
Beta	-69.38
Avg. Volume	1,929.14
PE Ratio	N/A

52-Week High	$0.0001
52-Week Low	$0.00
Market Capitalization	$62.00
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

ATHXQAthersys Inc

Latest ATHXQ News